Psoriasis and its treatment with adalimumab

Bibliography

• Nelson AA, Pearce DJ, Fleischer AB, New treatments for psoriasis: which biologic is best? J Dermatolog Treat 2006;17:96-107
   PubMed Web of Science ®Google Scholar
• About Psoriasis. Portland, Oregon: National Psoriasis Foundation 2009. Available from: http://www.psoriasis.org/about/psoriasis/ [Updated August 2009, Last accessed 19 November 2009]
   Google Scholar
• Gordon KB, Langley RG, Leonardi C, Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606
   PubMed Web of Science ®Google Scholar
• Managed Care Best Practices In The Treatment and Management of Psoriasis. Supplement to Managed Care Volume12 Number 5. Based on a Conference in Orlando Florida, Feb.3, 2003. Yardley, Pennsylvania Media Marketing USA. Available from: http://www.managedcaremag.com/supplements/0305_psoriasis_suppl/0305.psoriasis_suppl.pdf [Last accessed 19 November 2009]
   Google Scholar
• Krueger GG, Duvic M. Epidemiology of psoriasis: clinical issues. J Invest Dermatol 1994;102(6):14S-8S
   PubMed Web of Science ®Google Scholar
• Liu Y, Helms C, Liao W, A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PloS Genet 2008;4(3):e1000041. Published online 4 April 2008, doi:10.1371/journal.pgen.1000041
   PubMedGoogle Scholar
• Trembath RC, Clough RL, Rosbotham JL, Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997;6(5):813-20
   PubMed Web of Science ®Google Scholar
• Elder JT, Nair RP, Henseler T, The genetics of psoriasis 2001: the odyssey continues. Arch Dermatol 2001;137(11):1447-54
   PubMed Web of Science ®Google Scholar
• Bongiorno MR, Pistone G, Doukaki MA. Adalimumab for the treatment of moderate to severe psoriasis and psoriatic arthritis. Dermatol Ther 2008;21:S15-20
   Web of Science ®Google Scholar
• Fitch E, Harper E, Skorcheva I, Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007;9(6):461-7
   PubMedGoogle Scholar
• Fleischer AB, Feldman SR, Rapp SR. Introduction: the magnitude of skin disease in the United States. Dermatol Clin 2000;18(2):15-21
   Google Scholar
• Rich AJ, Bello-Quintero CE. Advancements in the treatment of psoriasis: role of biologic agents. J Manag Care Pharm 2004;10(4):318-25
   PubMedGoogle Scholar
• Rapp SR, Feldman SR, Exum ML, Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7
   PubMed Web of Science ®Google Scholar
• Van Voorhees AS, Fried R. Depression and quality of life in psoriasis. Postgrad Med 2009;121(4):154-61
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Feldman SR, Stern RS, Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004;51:704-8
   PubMed Web of Science ®Google Scholar
• Bhosle MJ, Feldman SR, Camacho FT, Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatolog Treat 2006;17:294-301
   PubMed Web of Science ®Google Scholar
• Ayala F, Ayala F. Clinical aspects and comorbidities of psoriasis. J Rheumatol Suppl 2009;83:19-20
   PubMedGoogle Scholar
• Nijsten N, Wakkee M. Complexity of the association between psoriasis and comorbidities. J Invest Dermatol 2009;129(7):1601-3
   PubMed Web of Science ®Google Scholar
• Mengesha YM, Bennett ML. Pustular skin disorders: diagnosis and treatment. Am J Clin Dermatol 2002;3(6):389-400
   PubMedGoogle Scholar
• Kerkhof PCM. Therapeutic strategies: rotational therapy and combinations. Clin Exp Dermatol 2001;26:356-61
   PubMed Web of Science ®Google Scholar
• Melnikova I. Psoriasis market. Nat Rev Drug Discov 2009;8:767-8
   PubMed Web of Science ®Google Scholar
• Original BLA for adalimumab (HUMIRA) in the treatment of rheumatoid arthritis. Washington DC: The Food and Drug Administration/USA – Department of Health and Human Services, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research: Statistical review(s) 125057.0. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm092773.pdf [Last accessed 19 November 2009]
   Google Scholar
• Saurat JH, Stingl G, Dubertret L, Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2007;158:558-66
   PubMed Web of Science ®Google Scholar
• Revicki D, Willian MK, Saurat JH, Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatolog 2008;158:549-57
   PubMed Web of Science ®Google Scholar
• Shikiar R, Heffernan M, Langley RG, Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a Phase II randomized controlled trial. J Dermatolog Treat 2007;18:25-31
   PubMed Web of Science ®Google Scholar
• Menter A, Stephen KT, Gordon K, Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Dermatol 2008;58:106-15
   PubMed Web of Science ®Google Scholar
• Revicki DA, Willian MK, Menter A, Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermtolog Treat 2007;18:341-50
   PubMed Web of Science ®Google Scholar
• Revicki DA, Menter A, Feldman S, Adalimumab improved health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes 2008;6:75. Published online 2 October 2008, doi:10.1186/1477-7525-6-75
   PubMed Web of Science ®Google Scholar
• Revicki DA, Willian MK, Menter A, Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 2008;216:260-70
   PubMed Web of Science ®Google Scholar
• Papoutsaki M, Chimenti MS, Constanzo A, Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007;57:269-75
   PubMed Web of Science ®Google Scholar
• Ardigo M, Guiliani A, deFelice C, Efficacy of adalimumab in plaque psoriasis: experience on 28 patients. J Drugs Dermatol 2008;7(10):935-9
   PubMedGoogle Scholar
• Vena GA, Galluccio A, De Simone C, A multicenter open-label experience on the response of psoriasis to adalimumab and effect of dose escalation in non-responders: the Aphrodite project. Int J Immunopathol Pharmacol 2009;22(1):227-33
   PubMed Web of Science ®Google Scholar
• Cassano N, Galluccio A, De Simone C, Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the Aphrodite data. J Biol Regul Homeost Agents 2008;22(4):233-7
   PubMed Web of Science ®Google Scholar
• Yamauchi PS, Mau N. Adalimumab treats psoriasis in patients previously treated with etanercept: a case series. J Am Acad Dtermatol 2009;61(1):158-60
   PubMed Web of Science ®Google Scholar
• Van L, Modi SV, Yang DJ, Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment. Arch Dermatol 2008;144(6):804-6
   PubMed Web of Science ®Google Scholar
• HUMIRA – European Public Assessment Report (EPAR) summary for the public. London, UK: European Medicines Agency (EMEA), 2008. Emea/H/C/481:1-3. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/humira/400803en1.pdf [Last accessed 19 November 2009]
   Google Scholar
• Scheifeld N. Adalimumab: a review of side effects. Exp Opin Drug Saf 2005;4(4):637-41
   PubMedGoogle Scholar
• Kavanagh PM, Gilmartin JJ, O'Donnell J, Tumour necrosis factor-alpha and tuberculosis: guidance from the national TB advisory committee. Air Med J 2008;101(1):6-7
   Google Scholar
• Wallis RS, Vuuren CV, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 2009;48:1429-32
   PubMed Web of Science ®Google Scholar
• Antolin J, Azahara M, Hernandez C, Tuberculosis peritonitis after treatment with adalimumab. Scand J Infect Dis 2008;40(8):677-8
   PubMed Web of Science ®Google Scholar
• Laffitte E, Janssens JP, Roux-Lombard P, Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs tuberculin skin test. Br J Dermatol 2009;161:797-800
   PubMed Web of Science ®Google Scholar
• Mangat P, Taylor P, Abraham S. Comment on: possible military tuberculosis during adalimumab therapy with negative interferon-gamma release assay. Rheumatol 2009;48:1177-8
   PubMed Web of Science ®Google Scholar
• Burmester GR, Mease P, Dijkmans BA, Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009;68(12):1863-9
   PubMed Web of Science ®Google Scholar
• Cancer Warnings Required for TNF Blockers. Washington, DC: Food and Drug Administration, 2009. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175803.htm [Last Accessed 19 November 2009]
   Google Scholar
• Patel RV, Clark LN, Lebwohl M, Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009;60:1001-17
   PubMed Web of Science ®Google Scholar
• Saraceno R, Schipani C, Mazzotta A, Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008;57:290-5
   PubMed Web of Science ®Google Scholar
• Asarch A, Gottlieb AB, Lee J, Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol 2009;61:104-11
   PubMed Web of Science ®Google Scholar
• Ghate JV, Alspaugh CD. Adalimumab in the management of palmoplantar psoriasis. Dermatol Online J 2009;15(7):15
   PubMedGoogle Scholar
• Rallis E, Korfitis C, Stavropoulou E, Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a class effect on TNF-alpha antagonists or simply an anti-psoriatic adverse reaction. J Dermatol Treat 2009: published online Jan 1:1-3, doi: 10.1080/09546630902882089
   Google Scholar
• Papadavid E, Dlamaga M, Stavrianeas N, Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-alpha therapy: a case series of four patients and guidelines for management. JEADV 2008;22:363-404
   Google Scholar
• Pelivani N, Hassan AS, Braathen L, Hunger RE. Alopecia areata universalis elicited during treatment with adalimumab. Dermatol 2008;216:320-3
   PubMed Web of Science ®Google Scholar
• Chaves Y, Duarte G, Ben-Said B, Alopecia areata universalis during treatment of rheumatoid arthritis with anti- TNF-alpha antibody (adalimumab). Dermatol 2008;217:380
   PubMed Web of Science ®Google Scholar
• Shabrawi-Caelen LE, LaPlaca M, Vincenzi C, Adalimumab – induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers. Inflam Bowel Dis Lett Ed 2009: published online 21 May 2009, doi: 10.1002/ibd.20954
   Google Scholar
• Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-alpha therapies. J Cutan Med Surg 2005;9(6):296-302
   PubMed Web of Science ®Google Scholar
• Trent JT, Kerdel FA. Using biologic agents off-label. Skin Aging 2005;13(11):1-5
   Google Scholar
• Traczewski P, Rudnicka L. Adalimumab in dermatology. Br J Clin Pharmacol 2008;66(5):618-25
   PubMed Web of Science ®Google Scholar
• Nelson AA, Pearce DJ, Fleischer AB, Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Dermatol 2008;58:125-35
   PubMed Web of Science ®Google Scholar